Medpal AI PLC - Launch of New Health dedicated GLP/peptides brand
MedPal AI plc
("MedPal AI" or the "Company")
Launch of New Health on new.co.uk as dedicated GLP-1 and peptides brand
New Health to operate as a specialist consumer brand within MedPal AI, positioned for GLP-1 growth and the expected
MedPal AI plc (AIM: MPAL; FRA: Z1N), the AI-native digital health and pharmacy platform, is pleased to announce the launch of New Health, a dedicated consumer sub-brand focused on the GLP-1 weight-management and broader peptide medicines market opportunity, supported by a
New Health will sit separately from the broader MedPal Clinic app and MedPal consumer platform. It has been created to give the Company a sharper consumer brand, acquisition funnel and patient journey for the highly competitive GLP-1 category, while continuing to use MedPal AI's regulated healthcare infrastructure comprising: AI-assisted intake, clinician-led assessment, prescribing where clinically appropriate, automated pharmacy dispensing and ongoing monitoring.
Highlights
· New Health launched as a specialist sub-brand of MedPal AI focused initially on GLP-1 weight management and, over time, the broader peptides opportunity.
· The sub-brand will operate separately from the MedPal Clinic app to allow a dedicated consumer proposition in a competitive, brand-led market, while remaining fully connected to MedPal AI's clinical, pharmacy and technology infrastructure.
·
· Marketing campaign is designed to drive traffic to websites new.co.uk and new.uk, to increase initiations of qualified consultations and to grow the New Health recurring patient base.
· Market context supported by published research indicating significant
· The Board anticipates that the potential
· New Health will be underpinned by MedPal AI's NHS-contracted dispensing hubs in
Strategic rationale: a focused sub-brand for a competitive market
The Board believes that the private GLP-1 weight-management market has become one of the most competitive areas of consumer healthcare, with patients comparing providers on the basis of brand trust, ease of access, clinical governance, price, prescription fulfilment and ongoing support. In this environment, the Board believes a specialist consumer brand is required to compete effectively with established online weight-management providers and pharmacy-led entrants.
New Health has, therefore, been created as a focused GLP-1 and peptides sub-brand within MedPal AI, with its own consumer positioning, website, campaign messaging and acquisition funnel. The purpose is not to replace the MedPal Clinic app, but to sit alongside it. New Health provides a specialist consumer entry point for this category, while the wider MedPal platform remains the Company's health operating system and regulated care infrastructure.
The Board believes this structure will allow MedPal AI to better compete at the same level as dedicated consumer brands in the GLP-1 market, while retaining the advantages of owned pharmacy infrastructure, human clinical oversight, AI-assisted patient engagement and longitudinal monitoring.
Market context: GLP-1 growth and oral pill opportunity
The Board notes published market research indicating that the GLP-1 category is expanding rapidly. Morgan Stanley Research has forecast that the global market for GLP-1 treatments could reach approximately
IQVIA evidence submitted to the
The Board anticipates that Novo Nordisk's once-daily oral semaglutide 25 mg weight-management pill, approved by the FDA in
Marketing and patient acquisition
The
The marketing spend is expected to be phased over six months and performance-led, with digital channels such as Google expected to be a principal component. Management will monitor traffic to new.co.uk, initial consultations, completed clinical assessments, conversion to new patient sign-ups, retention, customer acquisition cost and gross contribution, with the ability to increase, reduce or reallocate spend according to unit economics, patient-safety requirements and clinical/pharmacy capacity.
All New Health services and communications will be delivered subject to clinical eligibility, medicine availability, appropriate clinician review, prescription-only medicine rules and all applicable
Related party Transaction
CEO
At the end of six months, the Company will have the option to acquire the domain names.
Commenting on the launch,
"New Health is a focused sub-brand within MedPal AI for a specific opportunity: GLP-1 weight management and the broader peptides category. This market is highly competitive and brand-led, so we need a consumer proposition that can compete on the same terms - a simple brand, a clear message, a dedicated funnel and strong clinical governance behind it.
"MedPal AI remains the operating system for personal health. New Health is the specialist point of access for patients seeking GLP-1 weight-management support and, over time, broader peptide-led healthcare services where clinically appropriate. The patient sees a clear consumer brand; behind it sits MedPal's AI-assisted intake, clinicians, prescribing pathway, pharmacy fulfilment and monitoring.
"Our
Watch an interview with
https://www.youtube.com/watch?app=desktop&v=HjejrjlRG5Y&pp=iggCQAE%3D&ra=m
Ends
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic
Enquiries
|
MedPal AI plc |
via Square1 Consulting |
|
Cairn Financial Advisers LLP (Nominated Adviser) |
+44 (0) 20 7213 0880 |
|
Oak Securities (a trading name of Merlin Partners LLP) |
+44 (0) 20 3973 3678 |
|
Clear Capital Markets Limited |
+44 (0) 20 3869 6080 |
|
Square1 Consulting |
+44 (0) 20 7929 5599 |
About MedPal AI plc
MedPal AI plc (AIM: MPAL; FRA: Z1N) is a
Forward-looking statements
This announcement contains certain forward-looking statements, including statements regarding the Company's strategy, expected market developments, anticipated
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE